Business
CSL profits boom 45pc as flu business soars – The Australian Financial Review
The blood products giant notched up its fastest profit and revenue growth in recent years despite a uniquely challenging first half.
Sales of CSLs Hizentra product grew strongly, up 19 per cent, reflecting the benefits of home administration and the continued strong uptake for the treatment of the debilitating neurological disorder CIDP (chronic inflammatory demyelinating polyneuropathy).
The company declared a dividend of $US1.04 per share, up 9 per cent.
Guidance maintained
Despite the strong growth in the first half, the company maintained its full-year guidance of net profit of $US2.17 billion to $US2.265 billion at constant…
-
Noosa News12 hours agoMitch Power Quick Shear event gets men talking about mental health
-
General14 hours agoThailand punches above its weight in film creativity and cross-border appeal. Here’s why
-
Noosa News6 hours agoNRL live updates: Newcastle Knights vs Melbourne Storm, St George Illawarra Dragons vs Sydney Roosters, North Queensland Cowboys vs Canterbury Bulldogs
-
General7 hours agoAFL Round 18 live updates: Bulldogs vs Crows, Giants vs Cats, Tigers vs Bombers, Dockers vs Hawks — blog, scores and stats